Skip to main content
Brian Kelly

Brian Kelly, PhD, DABCC, FADLM

Languages spoken: English

Academic Information

Departments Adjunct - Pathology

Board Certification

  • American Board of Clinical Chemistry

Brian N. Kelly, PhD, DABCC, FADLM, After earning undergraduate degrees in Biochemistry and Molecular, Cellular, and Developmental Biology from the University of Colorado I pursued a PhD in Biochemistry from the University of Utah. Subsequently, I completed a 3-year post-doctoral fellowship in Clinical Chemistry and Laboratory Medicine at the University of Virginia. As a clinical toxicology specialist with ARUP, I review test results to investigate whether a patient is compliant with prescribed medications and not using illicit or non-prescribed medications. At ARUP, I also have the pleasure of teaching residents and fellows in Pathology. In my independent consulting business, I assist small to mid-size clinical laboratories in the implementation of liquid-chromatography mass-spectrometry based analysis of biological specimens, among other methods, as well as providing ongoing regulatory oversight.

Education History

Undergraduate University of Colorado
BA
Undergraduate University of Colorado
BA
Doctoral Training University of Utah
PhD
Fellowship University of Virginia
Clinical Research Fellow
Research Fellow Sports Medicine Research and Testing Laboratory
Research Fellow

Selected Publications

Journal Article

  1. Kelly BN, Howard BR, Wang H, Robinson H, Sundquist WI, Hill CP (2006). Implications for viral capsid assembly from crystal structures of HIV-1 Gag(1-278) and CA(N)(133-278). Biochemistry, 45(38), 11257-66.
  2. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, Stout CD, Sundquist WI, Hill CP, Yeager M (2009). X-ray structures of the hexameric building block of the HIV capsid. Cell, 137(7), 1282-92.
  3. Snozek CLH, Baskin LB, Boyd JM, Kelly BN, Krasowski MD, Sadrzadeh SMH, Tacker DH (2021). How Can Routine Clinical Laboratories Keep Up with the Opioid Crisis? Clin Chem, 67(2), 338-344.
  4. Kelly BN, Haverstick DM, Vance ML, Thorner MO, Bruns DE (2012). Quantification of growth hormone mRNA in blood. Clin Chim Acta, 414, 206-10.
  5. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, Robinson H, Sundquist WI, Summers MF, Hill CP (2007). Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol Biol, 373(2), 355-66.
  6. McMillin GA, Johnson-Davis KL, Kelly BN, Scott B, Yang YK (2021). Impact of the Opioid Epidemic on Drug Testing. Ther Drug Monit, 43(1), 14-24.
  7. Sundquist WI, Schubert HL, Kelly BN, Hill GC, Holton JM, Hill CP (2004). Ubiquitin recognition by the human TSG101 protein. Mol Cell, 13(6), 783-9.
  8. Kelly BN, Haverstick DM, Lee JK, Thorner MO, Vance ML, Xin W, Bruns DE (2014). Circulating microRNA as a biomarker of human growth hormone administration to patients. Drug Test Anal, 6(3), 234-8.
  9. Kelly BN, Madsen M, Sharpe K, Nair V, Eichner D (2013). A population study of urine glycerol concentrations in elite athletes competing in North America. Drug Test Anal, 5(11-12), 890-5.
  10. Yang YK, Johnson-Davis KL, Kelly BN, McMillin G (2020). Demand for Interpretation of a Urine Drug Testing Panel Reflects the Changing Landscape of Clinical Needs; Opportunities for the Laboratory to Provide Added Clinical Value. The journal of applied laboratory medicine, 5(5), 858-868.
  11. Boyd JM, Kelly BN, McMillin G (2024). Prevalence of Gabapentinoid and Opioid Copositives in a Reference Laboratory Patient Population. The journal of applied laboratory medicine, 9(4), 861-863.
  12. Kelly B (2023). UTI detection by PCR: Improving patient outcomes. Journal of mass spectrometry and advances in the clinical lab, 28, 60-62.

Commentary

  1. Brian N Kelly, Ph (2017). Sports Drug Testing Update.

Case Report

  1. Kelly, BN, Silverman, LM, Bruns, D (2013). Unexpected Serum Protein Electrophoresis Results: Finding the lost monoclonal protein.

Letter

  1. Kelly BN, Haverstick DM, Bruns DE (2010). Interference in a glucose dehydrogenase-based glucose meter. [Letter to the editor]. Clin Chem, 56(6), 1038-40.
  2. Kelly BN, Haverstick DM, Bruns DE (2012). Interference in a glucose dehydrogenase-based glucose meter revisited. [Letter to the editor]. Clin Chim Acta, 413(7-8), 829-30.

Video/Film/CD/Web/Podcast

  1. Brian N Kell (2009). One Cyclist's Experience.